Novo Nordisk has released the clinical trial data of its new diabetes drug, amycretin.
November 26, 2025
Source: drugdu
54
Novo Nordisk has released the clinical trial data for the new diabetes drug amycretin, showing that the drug not only lowers blood sugar but also has a significant weight loss effect.
The trial results indicate that the amycretin injection, administered once a week, can help patients lose up to 14.5% of their weight within 36 weeks; the oral formulation can achieve a weight loss of up to 10.1% per day.
This positive news has pushed the stock price of Novo Nordisk's US shares to rise, recovering most of the losses it suffered previously due to the failure of its Ozempic oral version to slow the progression of Alzheimer's disease in two clinical trials. Amycretin is a key component of Novo Nordisk's new drug portfolio, integrating two weight loss mechanisms into a single molecule, aiming to improve the company's competitive position in the field of obesity treatment.
https://finance.eastmoney.com/a/202511263574807587.html
By editor
Copyright©2025 Ddu. All rights reserved.
Read more on
- Multiple batches of quadrivalent influenza virus split vaccine have been sub-packaged and submitted for lot release approval; expected to be released to the market soon after approval December 12, 2025
- Ab&B Bio-Tech CO., LTD. JS Lyophilized Human Rabies Vaccine Initiates Phase III Clinical Trials December 12, 2025
- The ‘Sweetest’ HPV Vaccine Market is Gone | Haibin Interview December 12, 2025
- InnoCare Pharma announced that its first independently developed next-generation TRK inhibitor, zoletrazinib, has been approved for marketing in China December 12, 2025
- Is PD-1/VEGF dual antibody + ADC becoming the standard configuration? December 12, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
